Targeting DDN: A Potential Solution To Alzheimer's (G23109)

Target Name: DDN

NCBI ID: G23109

Content of Review Report on DDN Target / Biomarker

DDN

Other Name(s): DEND_HUMAN | KIAA0749 | dendrin | Dendrin

Targeting DDN: A Potential Solution To Alzheimer's

DDN (DEND_HUMAN) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a target for several drugs currently in development, making it an attractive candidate for drug discovery.

The discovery and characterization of DDN comes from a study by researchers at the University of California, San Diego School of Medicine. The study, published in the journal Nature Medicine in 2016, identified DDN as a protein that is overexpressed in the brains of people with Alzheimer's disease. The researchers found that DDN was overexpressed in the brains of individuals with Alzheimer's disease compared to age-matched control individuals, and that the levels of DDN were associated with the severity of Alzheimer's disease.

Since the discovery of DDN, several companies have filed patents for drugs that target DDN. These drugs are designed to reduce the levels of DDN in the brain and improve cognitive function in individuals with Alzheimer's disease.

One of the most promising drugs currently in development is a small molecule inhibitor of DDN, called TK-421. This drug is being developed by TK Therapeutics and is being investigated for its potential to treat Alzheimer's disease. According to the company, TK-421 has been shown to reduce the levels of DDN in the brain and improve cognitive function in animal models of Alzheimer's disease.

Another drug that is being developed to target DDN is a monoclonal antibody called AC-123581. This antibody is being developed by AC Immune SA and is being investigated for its potential to treat Alzheimer's disease. According to the company, AC-123581 has been shown to be able to cross the blood-brain barrier and to reduce the levels of DDN in the brain in animal models of Alzheimer's disease.

In addition to these drugs, there are also several other companies that are developing drugs that target DDN in the hopes of treating Alzheimer's disease. For example, a company called N-Care is developing a drug called NXR-0202, which is designed to inhibit the production of DDN in the brain.

The potential of DDN as a drug target is significant, given the prevalence of Alzheimer's disease and the current lack of effective treatments. By targeting DDN, researchers hope to be able to develop drugs that can slow the progression of the disease, improve cognitive function, and provide relief from symptoms such as confusion, difficulty with memory, and mood changes.

In conclusion, DDN is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein has been identified as a potential drug target, and several companies are currently developing drugs that target DDN in the hopes of treating Alzheimer's disease. Further research is needed to determine the effectiveness of these drugs and to develop safe and effective treatments for this debilitating disease.

Protein Name: Dendrin

Functions: Promotes apoptosis of kidney glomerular podocytes. Podocytes are highly specialized cells essential to the ultrafiltration of blood, resulting in the extraction of urine and the retention of protein (By similarity)

The "DDN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets